Skip to main content

Helixgate

Skip to main content

Helixgate

AI, Machine Learning & Computational Biology

STAT+: Novo Nordisk’s high-dose Wegovy approved in the U.S.

A high-dose version of Novo Nordisk’s injectable obesity drug Wegovy received U.S. approval, the company said Thursday, providing it with a new catalyst as it tries to claw back market share with its weight loss treatments.

The therapy was approved under a new voucher program that was set up by Food and Drug Administration Commissioner Marty Makary and that was intended to accelerate review of drugs that align with national priorities. Novo received the voucher as part of its deal with the Trump administration late last year to lower prices of its obesity medicines in certain settings.

Novo was first to open up the booming obesity market with Wegovy, but it’s fallen behind Eli Lilly in recent years, and it’s not clear how much high-dose Wegovy will help it become more competitive again.

Continue to STAT+ to read the full story…

Read More

Published

on

A high-dose version of Novo Nordisk’s injectable obesity drug Wegovy received U.S. approval, the company said Thursday, providing it with a new catalyst as it tries to claw back market share with its weight loss treatments.

The therapy was approved under a new voucher program that was set up by Food and Drug Administration Commissioner Marty Makary and that was intended to accelerate review of drugs that align with national priorities. Novo received the voucher as part of its deal with the Trump administration late last year to lower prices of its obesity medicines in certain settings.

Novo was first to open up the booming obesity market with Wegovy, but it’s fallen behind Eli Lilly in recent years, and it’s not clear how much high-dose Wegovy will help it become more competitive again.

Continue to STAT+ to read the full story…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

AI, Machine Learning & Computational Biology

AI is changing the talent biotech companies compete to hire

As AI becomes more embedded in biotech R&D, companies are competing for professionals who can bridge biology, machine learning, data and engineering. Recruiting expert Darren Nelson explains which capabilities are becoming hardest to find—and why.

Published

on

AI is changing the talent biotech companies compete to hire
As AI becomes more embedded in biotech R&D, companies are competing for professionals who can bridge biology, machine learning, data and engineering. Recruiting expert Darren Nelson explains which capabilities are becoming hardest to find—and why.
Continue Reading

AI, Machine Learning & Computational Biology

Consolidating Antibody Discovery Data with an AI Platform

The Sapio Scientific AI platform gives scientists a single, structured environment where experimental records connect directly to client deliverables and where time spent on data consolidation becomes time spent on science.

The post Consolidating Antibody Discovery Data with an AI Platform appeared first on GEN – Genetic Engineering and Biotechnology News.

Published

on

Consolidating Antibody Discovery Data with an AI Platform

FairJourney Bio (FJBio) selected the Sapio Scientific AI platform, including Sapio’s LIMS, ELN, and AI co-scientist solutions to replace spreadsheet-based records and manual reporting processes across its international operations.

FJBio is a global antibody discovery and engineering partner. Founded in 2012, the company works on taking programs from target to preclinical candidate within a single integrated workflow, run by one team across three centers of excellence: Porto (Portugal), Cambridge (U.K.), and San Diego (U.S.). The antibody company completed more than 1,400 programs for over 250 industry partners across pharma, biotech, and academia, with 20 partner assets in clinical trials.

The volume and complexity of experimental data generated across those programs made consistent, structured records a scientific and operational priority for FJBio, according to Sapio Sciences’ CCO Mike Hampton, who added that the company’s AI platform will serve as the informatics backbone across all of FJBio’s discovery and cell sciences operations.

Provides a single entity registry

Sapio’s ELN solution will record experimental data across phage display, screening, and cell sciences programs, replacing the need for scientists to capture data on paper templates before manually re-entering results into spreadsheets. As FJBio’s program portfolio has grown across three sites, the Sapio LIMS gives the company a single entity registry, from target registration through clone identification and screening results, searchable across programs, points out Hampton.

The solution is also designed to ensure integration of lab instruments, connecting instrument output directly to Sapio’s experiment records and eliminating manual data transcription at the bench. Structured client data reports, that were assembled by hand from individual experiment records will now come straight out of the platform, expected to return up to 40% of scientific staff time back to discovery, says a Sapio spokesperson.

“FairJourney Bio runs discovery programs of genuine depth and complexity across multiple international sites,” comments the spokesperson. “The Sapio Scientific AI platform gives their scientists a single, structured environment where experimental records connect directly to client deliverables and where time spent on data consolidation becomes time spent on science.”

digital dna
FairJourney Bio selected the Sapio Scientific AI platform, including Sapio’s LIMS, ELN, and AI co-scientist solutions. [BlackJack3D/Getty Images]
Sapio’s Scientific AI Platform data model, and its ability to support full traceability from target registration through screening and hit identification, provided the technical foundation FJBio needed, states José Vidal, COO at FJBio. The inclusion of Elain, Sapio’s native AI co-scientist, rather than a bolt-on capability, was a further differentiator for FJBio as it looks to build long-term informatics capability alongside its expanding discovery operations.

“As our operations have grown across three international sites, we needed an informatics platform that could keep pace with that responsibility,” says Vidal. “The Sapio Platform gives our scientists a single connected environment for every experiment, every sample and every result, and it holds that data to the integrity and security standards our clients expect.”

Elain brings intelligence directly into FJBio’s scientific workflows, says Hampton. Working across the structured experimental data held within the Sapio Platform, Elain enables scientists to interact with their data using natural language, without leaving the environment where their experiments, samples and results are managed, he explains.

 

The post Consolidating Antibody Discovery Data with an AI Platform appeared first on GEN - Genetic Engineering and Biotechnology News.

Continue Reading

AI, Machine Learning & Computational Biology

AI automates 3D membrane mapping, matching manual results in a fraction of time

Cell membranes and the proteins within them control many vital processes and play a key role in health and disease. But studying them in 3D images of cells has so far meant slow, manual work. A team from Helmholtz Munich, the Technical University of Mu…

Published

on

AI automates 3D membrane mapping, matching manual results in a fraction of time
Cell membranes and the proteins within them control many vital processes and play a key role in health and disease. But studying them in 3D images of cells has so far meant slow, manual work. A team from Helmholtz Munich, the Technical University of Munich (TUM) and the Biozentrum of the University of Basel has developed MemBrain v2, an AI tool that automates this task—cutting work that once took weeks down to a few hours. The study is published in Nature Methods.
Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read